We advised WSE-listed Genomtec S.A. on a non-brokered public offering

We advised WSE-listed Genomtec S.A. on a non-brokered public offering of the company’s shares carried out under an accelerated bookbuilding procedure (ABB) and a related private placement of the company’s new issue shares.

The public offering included 1,237,000 series M new issue shares and 900,000 existing WSE-listed shares of the company offered by its shareholder Leonarto Funds SCSp. The shares offered by the shareholder were previously borrowed for this purpose from other shareholders of the company. The public offering was targeted at qualified investors and selected retail investors.
As part of the private placement, the company issued 400,000 N shares, which were subscribed for by Leonarto Funds SCSp for the purpose of reinvesting the funds raised from the sale of the company’s shares in the public offering (including the funds allocated for the shareholder’s purchase of part of the M shares).
The total value of the public offering and the private placement amounted to PLN 20,296,000.
We supported the company in all legal aspects of the transaction. The scope of advisory services included, in particular, advising on the transaction structuring process, preparing and negotiating transaction documentation (including the investment agreement, loan agreements, issue documentation), advising on the implementation of the Company’s disclosure obligations, and providing legal advice on the process of dematerialization of new issue shares and admission of series M shares to trading on the regulated market of the WSE.
Bookkeeping for the shares offered in the public offering was entrusted to Brokerage INC S.A. In terms of Investor Relations, the company was also supported by cc group.

We thank Genomtec S.A. and the other advisors involved in the transaction for their fruitful cooperation and trust.
The project supervised by Krzysztof Marczuk was managed by Michal Wielinski supported by Jakub Rowicki. The project team also included Michal Dunikowski.

Genomtec S A. is a technology company operating in the field of clinical diagnostics. It was founded in 2016 in Wroclaw, Poland, with a vision of international expansion based on a unique mobile genetic diagnostics platform using a patented non-contact heating and detection system. The company, founded by a group of scientists with experience and expertise in the fields of molecular biology and microsystems and photonics, has its headquarters and laboratories in Wroclaw. Genomtec also has an office in the UK, where part of its international research and engineering team is located.